Your account is not claimed yet. You can sign up with ORCID to claim your account.

Thomas H Keller

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 3

Top Topics

Top Venues

The Journal of experimental medicine

Molecular cancer therapeutics

Journal of cell science

Experimental Drug Development Centre

University of British Columbia (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Experimental Drug Development Centre Oct 1o 2018

Singapore

Director :: Discovery Chemistry

Education History

University of British Columbia

Canada

PHD :: Chemistry

Publications

Jia Yu, Pei Ju Liao, Weijun Xu, Julie R Jones, David B Everman, Heather Flanagan-Steet, Thomas H Keller, David M Virshup
Structural model of PORCN illuminates disease-associated variants and drug binding sites. Journal of cell science (2021)
Guoxing Zhang, Zhen Dong, Ryan N Gimple, Arthur Wolin, Qiulian Wu, Zhixin Qiu, Lisa M Wood, Jia Z Shen, Li Jiang, Linjie Zhao, Deguan Lv, Briana C Prager, Leo J Y Kim, Xiuxing Wang, Lingdi Zhang, Ryan L Anderson, Jeffrey K Moore, Shideng Bao, Thomas H Keller, Grace Lin, CongBao Kang, Petra Hamerlik, Rui Zhao, Heide L Ford, Jeremy N Rich
Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. The Journal of experimental medicine 218 (11) (2021)
Jothi Anantharajan, Hengbo Zhou, Lingdi Zhang, Taylor Hotz, Melanie Y Vincent, Melanie A Blevins, Anna E Jansson, John Wee Liang Kuan, Elizabeth Yihui Ng, Yee Khoon Yeo, Nithya Baburajendran, Grace Lin, Alvin W Hung, Joma Joy, Samarjit Patnaik, Juan Marugan, Pratyaydipta Rudra, Debashis Ghosh, Jeffrey Hill, Thomas H Keller, Rui Zhao, Heide L Ford, CongBao Kang
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells. Molecular cancer therapeutics 18 (9) (2019)